Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Active not recruiting 81Recruiting 58Completed 32Terminated 12Not yet recruiting 9Withdrawn 2Suspended 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Urinary Bladder Neoplasms 1Pancreatic Neoplasms 1

Interventions

Specimen Handling 35Magnetic Resonance Spectroscopy 23Biopsy 22Cyclophosphamide 11venetoclax 7Nivolumab 6Azacitidine 6pembrolizumab 5Taxes 5Etoposide 5Cisplatin 5Bevacizumab 5fludarabine phosphate 4fludarabine 4X-Rays 4Vincristine 4Surgical Procedures, Operative 4Radiosurgery 4Radiation 4Gemcitabine 4Doxorubicin 4Cetuximab 4130-nm albumin-bound paclitaxel 4durvalumab 3decitabine and cedazuridine drug combination 3cemiplimab 3Tacrolimus 3Surveys and Questionnaires 3Radiotherapy, Intensity-Modulated 3Prednisone 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Suspended × olaparib × 1 year × Clear all
NCT05411094 2026-06-15

Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer

National Cancer Institute (NCI)

Phase 1 Suspended
18 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT03375307 2026-06-05

Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes

National Cancer Institute (NCI)

Phase 2 Suspended
60 enrolled
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡